ATE222489T1 - Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren - Google Patents

Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren

Info

Publication number
ATE222489T1
ATE222489T1 AT98955056T AT98955056T ATE222489T1 AT E222489 T1 ATE222489 T1 AT E222489T1 AT 98955056 T AT98955056 T AT 98955056T AT 98955056 T AT98955056 T AT 98955056T AT E222489 T1 ATE222489 T1 AT E222489T1
Authority
AT
Austria
Prior art keywords
thyroxine
malignant tumors
ketone
treatment
significant hormonal
Prior art date
Application number
AT98955056T
Other languages
English (en)
Inventor
Ernest Kun
Jerome Mendeleyev
Kalman G Buki
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octamer Inc filed Critical Octamer Inc
Application granted granted Critical
Publication of ATE222489T1 publication Critical patent/ATE222489T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT98955056T 1997-10-23 1998-10-23 Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren ATE222489T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/956,711 US5922775A (en) 1997-10-23 1997-10-23 Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
PCT/US1998/022383 WO1999020263A1 (en) 1997-10-23 1998-10-23 Thyroxine analogues having no significant hormonal activity to treat malignant tumors

Publications (1)

Publication Number Publication Date
ATE222489T1 true ATE222489T1 (de) 2002-09-15

Family

ID=25498590

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955056T ATE222489T1 (de) 1997-10-23 1998-10-23 Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren

Country Status (7)

Country Link
US (1) US5922775A (de)
EP (1) EP1024800B1 (de)
AT (1) ATE222489T1 (de)
AU (1) AU1195499A (de)
DE (1) DE69807349T2 (de)
ES (1) ES2181298T3 (de)
WO (1) WO1999020263A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6433012B1 (en) * 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
AU3109199A (en) * 1998-03-25 1999-10-18 Large Scale Biology Corporation Benzoates derivatives for inhibiting angiogenesis
US6326402B1 (en) * 1998-08-12 2001-12-04 Octamer, Inc. Methods for treating viral infections using a compound capable of inhibiting microtubules
AU1624801A (en) 1999-11-19 2001-05-30 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
EP1689383B1 (de) * 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Neue phosphor enthaltende thyromimetika
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
CN101522609A (zh) 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
AU2007292302A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
EP2211854A4 (de) * 2007-10-19 2011-01-12 Bipar Sciences Inc Verfahren und zusammensetzungen zur behandlung von krebs mit parp-inhibitoren vom benzopyrontyp
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
US20090275608A1 (en) * 2008-02-04 2009-11-05 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018215447A1 (en) * 2017-02-03 2019-08-08 The Regents Of The University Of California Compositions and methods for inhibiting reticulon 4
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Methods of treating glioblastoma
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
JP2021534214A (ja) * 2018-08-24 2021-12-09 ゼニオプロ ゲーエムベーハー 抗増殖活性を有するフェノキシ（ヘテロ）アリールエーテル
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB642159A (en) * 1947-10-23 1950-08-30 Glaxo Lab Ltd Improvements in or relating to the preparation of diphenyl ethers
GB643089A (en) * 1947-10-23 1950-09-15 Glaxo Lab Ltd Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
GB9211415D0 (en) * 1992-05-29 1992-07-15 Ici Plc Process for the production of purified terephthalic acid
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Also Published As

Publication number Publication date
EP1024800A1 (de) 2000-08-09
DE69807349T2 (de) 2003-01-02
AU1195499A (en) 1999-05-10
WO1999020263A1 (en) 1999-04-29
EP1024800B1 (de) 2002-08-21
DE69807349D1 (de) 2002-09-26
US5922775A (en) 1999-07-13
ES2181298T3 (es) 2003-02-16

Similar Documents

Publication Publication Date Title
ATE300292T1 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
DE69807349D1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE69127175D1 (de) Antisens-Oligonukleotide zur Behandlung von Krebs
DE69839586D1 (de) Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE69737066D1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ATE249233T1 (de) Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen
NO994330D0 (no) Metode for behandling av en tumor
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DE59911556D1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
DE69231465D1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1024800

Country of ref document: EP